U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said his department, working with the National Institutes of Health, has begun studies into whether selective serotonin reuptake inhibitors and other psychiatric or gender-transition drugs contribute to suicidal thoughts or violent behavior. Kennedy announced the initiative one day after a shooting at a Catholic school in Minneapolis that left two children dead and 17 others injured. Police have identified the suspected attacker as a 23-year-old transgender individual, intensifying scrutiny of medications commonly prescribed to people undergoing gender transition. Many of the drugs under review carry Food and Drug Administration black-box warnings for suicidal or homicidal ideation, but federal officials say they have not been systematically studied for possible links to aggression. The research will analyze prescribing patterns, adverse-event reports and epidemiological data; no timetable or budget figures have yet been released. Kennedy’s move drew conflicting reactions. Supporters argue a federal review is overdue, noting that roughly 10 percent of U.S. adults take antidepressants, while critics—including a Minnesota senator—accused the secretary of stoking unfounded fears rather than focusing on gun-violence prevention.